-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Emicizumab is a bispecific monoclonal antibody that can link activating factor (F) IX and FX and maintain hemostasis in patients with hemophilia A (PwHA)
.
As a new type of drug, due to the development of anti-drug antibodies (ADA), many questions remain unanswered, such as the loss of efficacy of emicizumab, the incidence of inhibitor recurrence in previously tolerated patients, and the risk of de novo inhibitor development
Emicizumab is a bispecific monoclonal antibody that can link activating factor (F) IX and FX and maintain hemostasis in patients with hemophilia A (PwHA)
Table 1: Patient characteristics
Table 1: Patient characteristicsTable 2: Major Adverse Events The results of this study showed that of 52 patients, 4 had minor adverse events, 2 had headaches, 1 had abdominal pain and nausea, and 1 had injection site reactions
.
In addition, four patients experienced serious adverse events, including severe headaches, major bleeding events, development of ADAs, and recurrence of inhibitors
Table 2: Major Adverse Events The results of this study showed that of 52 patients, 4 had minor adverse events, 2 had headaches, 1 had abdominal pain and nausea, and 1 had injection site reactions
Original source:
Hassan, E ,Jonathan, L ,Jayashree, M .
Real-World preference Experience ON The tolerability and Safety of emicizumab prophylaxis in Pediatric patients with Severe Haemophilia A with and the without of FVIII inhibitors .
Haemophilia .
2021 ;27 :E698 -E703 .
HTTPS: / /doi.
org/10.
Hassan, E , Jonathan, L , Jayashree, M .
Real-World preference Experience ON The tolerability and Safety of emicizumab prophylaxis in Pediatric patients with Severe Haemophilia A with and the without of FVIII inhibitors .
Haemophilia .
2021 ; 27 : E698 - E703 .
HTTPS: / /doi.
org/10.
1111/hae.
14432 Leave a message here
